Cargando…

The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis

Background and Objectives: Iron deficiency and anemia characterize patients on chronic hemodialysis (HD). Available intravenous iron agents, such as ferric gluconate (FG) and ferric carboxymaltose (FCM), vary in dosing regimens and safety profiles. The aim of the present study was to analyze the mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacquaniti, Antonio, Gargano, Romana, Campo, Susanna, Casuscelli di Tocco, Teresa, Schifilliti, Silvia, Monardo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305135/ https://www.ncbi.nlm.nih.gov/pubmed/37374275 http://dx.doi.org/10.3390/medicina59061071

Ejemplares similares

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
por: Lacquaniti, Antonio, et al.
Publicado: (2020)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study
por: Rosati, Alberto, et al.
Publicado: (2022)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
por: Rognoni, Carla, et al.
Publicado: (2019)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency
por: Calvet, Xavier, et al.
Publicado: (2012)

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
por: Emrich, I. E., et al.
Publicado: (2020)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Ferric Carboxymaltose in the Treatment of Iron-Deficiency Anaemia in Paediatric Patients with Anastomotic Ulcers
por: Udina, Chiara, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding
por: Hagras, Ahmed M., et al.
Publicado: (2022)

Ferric Carboxymaltose-Mediated Attenuation of Doxorubicin-Induced Cardiotoxicity in an Iron Deficiency Rat Model
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
por: Froessler, Bernd, et al.
Publicado: (2018)

Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion
por: Mishra, Vineet, et al.
Publicado: (2018)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)

A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose
por: Pollock, Richard F., et al.
Publicado: (2022)

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
por: Hussain, Iftikhar, et al.
Publicado: (2013)

Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review
por: Aksan, Aysegül, et al.
Publicado: (2022)

Induction of tumours in mice and rats with ferric sodium gluconate and iron dextran glycerol glycoside.
por: Carter, R. L., et al.
Publicado: (1968)

Treatment of Iron Deficiency With Intravenous Ferric Carboxymaltose in General Practice: A Retrospective Database Study
por: Kuster, Martina, et al.
Publicado: (2015)

Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial
por: Trenkwalder, Claudia, et al.
Publicado: (2017)

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
por: Bourguignon, Sandrine, et al.
Publicado: (2019)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long‐term study
por: Kramer, Tilmann, et al.
Publicado: (2021)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Rhabdomyolysis after Intravenous Ferric Gluconate: A Case Report
por: Botti, Mara, et al.
Publicado: (2022)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
por: Steinmetz, T., et al.
Publicado: (2013)

Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women
por: Rathod, Setu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fm2q4q9alp2ibu8srjom2hr4ka